Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Extending half-life in coagulation factors: where do we stand?

Thrombosis research - 1 Jan 2008

Lillicrap David

Abstract excerpt

The human coagulation factor VIII (FVIII) and von Willebrand factor (VWF) are two distinct glycoproteins that circulate in the plasma as a non-covalently bound complex (VWF/FVIII complex). Deficiencies or structural defects in FVIII and VWF are responsible for the most common inherited plasma bleeding disorders haemophilia A and von Willebrand disease (VWD), respectively. Current therapies for the treatment of...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Factor VIII
Share to VWF gene
Share to Half-Life

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Hemophilia A

Share to Metabolic Clearance Rate

Share to Mutation

Share to von Willebrand Factor

Source

Identifiers

PMID: 18929522
DOI: 10.1016/S0049-3848(08)70027-6

Genes

VWF

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 5 Sept 2026. Manifest publication-graph-cohort-2026-09-05.1.

Source receipt: pubmed, retrieved 5 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Extending half-life in coagulation factors: where do we stand?PMID 18929522Read ↗

The Evolution of Hemophilia Care: Clinical and Laboratory Advances, Opportunities, and ChallengesSemantic proximity Read ↗

Blood coagulation factor VIII: An overview.Semantic proximity Read ↗

Recent Advances in the Treatment of Hemophilia: A ReviewSemantic proximity Read ↗

Many factor VIII products available in the treatment of hemophilia A: an embarrassment of riches?Semantic proximity Read ↗

Navigation of the Hemophilia Drug Choice-Paralysis: A Quick User Guide to New and Existing TherapiesSemantic proximity Read ↗

Changing Paradigm of Hemophilia Management: Extended Half-Life Factor Concentrates and Gene TherapySemantic proximity Read ↗

Emerging therapies for hemophilia: controversies and unanswered questionsSemantic proximity Read ↗

The long and short of it: using the new factor products.Semantic proximity Read ↗

Emerging and future therapies for hemophiliaSemantic proximity Read ↗

Treatment of von Willebrand DiseaseSemantic proximity Read ↗

The hope and reality of long‐acting hemophilia productsSemantic proximity Read ↗

Transition considerations for extended half‐life factor productsSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.